MOTS-c Guide

MOTS-c at a glance

What it is

A 16-amino-acid mitochondrial-derived peptide encoded within the 12S rRNA region of mitochondrial DNA

Researched for

Metabolic regulation, insulin sensitivity, and exercise/mitochondrial biology in preclinical models

Commonly reported range

Community-reported examples of roughly 5-10 mg per injection (no established human dose)

Route reported

Subcutaneous injection (research context)

Reported frequency

2-3 times per week is a commonly cited example

Reported cycle

Community examples of 4-8 weeks on, then a break

Plasma half-life

No published human PK; rodent data suggest roughly 1-2 hours

Regulatory status

Not FDA-approved; research-use only; explicitly prohibited by WADA (AMPK activator)

Reported ranges from research/community — examples, not recommendations.

What it is / mechanism

MOTS-c (Mitochondrial ORF of the 12S rRNA type-c) is a small peptide encoded within mitochondrial DNA rather than the nuclear genome. In published research it is described as translocating from the mitochondria to the cell nucleus under metabolic stress, where it is reported to influence gene expression tied to metabolism and antioxidant responses. A central reported mechanism is activation of the AMPK pathway, a cellular energy sensor that regulates glucose uptake and fatty-acid metabolism. Studies have also linked MOTS-c to the Nrf2 antioxidant response and to improved mitochondrial homeostasis in animal and cell models. Because it acts on intracellular signaling rather than a high-affinity surface receptor, it is studied at substantially higher doses than typical receptor-binding peptides.

Researched effects

In preclinical research, MOTS-c has been associated with improved insulin sensitivity, enhanced glucose regulation, resistance to diet-induced obesity in mice, and markers consistent with improved exercise capacity and mitochondrial function. Some researchers describe it as an "exercise mimetic" based on animal data. These are research findings, not guaranteed outcomes; the great majority of evidence comes from cell and rodent studies, and rigorous human trials establishing efficacy, dosing, or safety have not been published.

Dosage — reported ranges (overview)

There is no established or approved human dose for MOTS-c. The figures below are examples of what is reported in community and preclinical literature, not a recommendation. Preclinical rodent studies frequently used intraperitoneal doses expressed per kilogram (for example around 0.5 mg/kg), which do not translate directly to humans. In community research-use discussion, examples commonly cited are roughly 5-10 mg per subcutaneous injection, 2-3 times per week, in cycles of about 4-8 weeks followed by a break. Because MOTS-c is reported to influence glucose metabolism, discussions frequently caution about combining it with other glucose-lowering agents.

The full step-by-step protocol examples, titration, and printable protocol sheet are planned for a future paid Protocol Playbook module.

Reconstitution — bac-water math

MOTS-c is dosed in milligrams, so reconstitution is concentration math. Add bacteriostatic water to the lyophilized vial and the concentration equals total peptide divided by the water volume: concentration (mg/mL) = vial mg / water mL. On a U-100 insulin syringe, 1 mL = 100 units, so units to draw = (desired mg / concentration) x 100. Worked example: a 10 mg vial reconstituted with 2 mL of bacteriostatic water gives 5 mg/mL. A 5 mg example dose is then 1 mL, which is 100 units on a U-100 syringe; a 10 mg example dose would be 2 mL (drawn as two full syringes). Choosing 1 mL of water instead concentrates it to 10 mg/mL so a 5 mg dose is just 50 units. This is concentration math, not a personal dose.

This is concentration math, not a dose recommendation.

Injection / administration basics

In the research context, MOTS-c is reconstituted with bacteriostatic water, drawn into a U-100 insulin syringe, and administered subcutaneously (commonly into abdominal fat). Standard aseptic handling is described: swab the vial stopper and injection site with alcohol, add water slowly against the vial wall rather than directly onto the powder, swirl gently rather than shaking, and rotate sites to reduce local irritation. Because example doses of 10 mg can exceed the 100-unit capacity of a single U-100 syringe at lower concentrations, a higher-concentration reconstitution is often chosen to keep the draw manageable. These are general handling notes, not medical instructions.

Half-life & frequency rationale

There is no published human pharmacokinetic data for MOTS-c. Rodent data suggest a relatively short plasma half-life on the order of roughly 1-2 hours after administration. Mitochondrial-derived peptides in general are reported to have low bioavailability, limited stability, and short circulating half-lives, which is one reason infrequent but relatively large doses appear in community protocols. Actual half-life, bioavailability, and tissue distribution in humans remain undefined.

Stacking — overview

In community research-use discussion, MOTS-c is often described alongside other metabolic and mitochondrial-support compounds, on the rationale of complementary energy and metabolic pathways. Any combination compounds theoretical glucose-lowering and unknown-safety concerns, and none of these pairings are clinically validated. The stacks below are examples of what is reported, not recommendations.

Storage & handling

• Lyophilized (powder): store sealed and protected from light; refrigeration is commonly recommended, and long-term storage is often at freezer temperatures. Keep away from heat and moisture until reconstituted.
• Reconstituted (in bacteriostatic water): keep refrigerated at approximately 2-8 C and use within a few weeks; avoid freezing the reconstituted solution and do not shake vigorously.

Guide FAQ

Quick answers about guide scope, access, and educational use context.